ASCVD Playbook | Closing the Gaps, One Inning at a Time
J.A. Randy Englert, MD, FACC
Matthew Malachowski, Pharm. D., MHA
Leadoff Hitter – Spotting High-Risk Players
Turning the Double Play – Comprehensive Secondary Prevention
Crossing Home Plate – Building a Winning Team Culture
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Overcoming Practical Barriers to Treatment in the Era of Myosin Inhibitors
Florian Rader, MD
Modern Obstructive HCM Care: From Unmet Needs to Individualized Myosin Inhibitor Therapy
Anjali Owens, MD
Ahmad Masri, MD, MS
Cracking the Code of Obstruction: Unmet Needs in oHCM
Michael Nassif, MD, MSc
Molecular Precision: How Myosin Inhibitors Redefine Control
From Beta-Blockers to Myosin Inhibitors: Initial Decision-Making in Obstructive HCM
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
The Overlooked Valve: Why Women With Aortic Stenosis Fall Through the Cracks
Pam R. Taub, MD, FACC, FASPC
Advancing Care for Women With Aortic Stenosis*: 2-Year Outcomes for Women in the 5-Year SMART Trial
Roxana Mehran, MD, FSCAI
Kappa-Opioid Settings: Real-World Evidence Insights
Lucio Manenti, MD, PhD
Emilio Sanchez, MD, PhD